Lanthanum salts improve bone formation in a small animal model of post-menopausal osteoporosis

Journal of Animal Physiology and Animal Nutrition

Volumn 96, Issue 5, 2012, Pages 885-894

  von Rosenberg, S J ^a   Wehr, U A ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Bavarian Health and Food Safety Authority LGL   (Germany)

Author keywords

Bone formation; Bone marker; Bone mineral density; Lanthanides; Ovariectomized rat; Post menopausal osteoporosis; Rare earth elements

Indexed keywords

CALCIUM; CITRIC ACID; LANTHANUM; LANTHANUM CARBONATE; LANTHANUM CITRATE;

ANIMAL; ARTICLE; BONE DENSITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; METABOLISM; OSTEOPOROSIS; OVARIECTOMY; RAT;

ANIMALS; BONE DENSITY; CALCIUM; CITRATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; LANTHANUM; OSTEOPOROSIS; OVARIECTOMY; RATS;

ANIMALIA; RATTUS;

EID: 84865977015     PISSN: 09312439     EISSN: 14390396     Source Type: Journal    
DOI: 10.1111/j.1439-0396.2012.01326.x     Document Type: Article

References (53)

1. American Food and Drug Administration, 1994: Guidelines for Preclinical and Clinical Evaluation of Agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products. Draft.
2. Behets, G. J.; Dams, G.; Vercauteren, S. R.; Damment, S. J.; Bouillon, R.; De Broe, M. E.; D' Haese, P. C., 2004a: Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? Journal of the American Society of Nephrology 15, 2219-2228.
3. Behets, G. J.; Verberckmoes, S. C.; D′ Haese, P. C.; De Broe, M. E., 2004b: Lanthanum carbonate: a new phosphate binder. Current Opinion in Nephrology and Hypertension 13, 403-409.
4. Black, D.; Duncan, A.; Robins, S. P., 1988: Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phased high performance liquid chromatography. Analytical Biochemistry 169, 197-203.
5. Bollag, R. J.; Zhong, Q.; Phillips, P.; Min, L.; Zhong, L.; Cameron, R.; Mulloy, A. L.; Rasmussen, H.; Qin, F.; Ding, K. H.; Isales, C. M., 2000: Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141, 1228-1235.
6. Bollag, R. J.; Zhong, Q.; Ding, K. H.; Phillips, P.; Zhong, L.; Qin, F.; Cranford, J.; Mulloy, A. L.; Cameron, R.; Isales, C. M., 2001: Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Molecular and Cellular Endocrinology 177, 35-41.
7. Brown, J. P.; Josse, R. G., 2002: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Canadian Medical Association Journal 167(10 Suppl.), 1-34.
8. Colwell, A.; Russel, R. G.; Eastell, R., 1993: Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. European Journal of Clinical Investigation 23, 341-349.
9. D' Haese, P. C.; Spasovski, G. B.; Sikole, A.; Hutchison, A.; Freemont, T. J.; Sulkova, S.; Swanepoel, C.; Pejanovic, S.; Djukanovic, L.; Balducci, A.; Coen, G.; Sulowicz, W.; Ferreira, A.; Torres, A.; Curic, S.; Papovic, M.; Dimkovic, N.; De Broe, M. E., 2003: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney International. Supplement 85, S73-S78.
10. Damment, S. J. P.; Pennick, M., 2008: Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clinical Pharmacokinetics 47, 553-563.
11. Durbin, P. W.; Williams, M. H.; Gee, M.; Newman, R. H.; Hamilton, J. G., 1956: Metabolism of the lanthanons in the rat. Proceedings of the Society for Experimental Biology and Medicine 91, 78-85.
12. Erben, R. G.; Scutt, A. M.; Miao, D.; Kollenkirchen, U.; Haberey, M., 1997: Short-term treatment of rats with high dose 1, 25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 138, 4625-4629.
13. Erben, R. G.; Bromm, S.; Stangassinger, M., 1998: Therapeutic efficacy of 1alpha, 25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1alpha, 25-dihydroxyvitamin D3 on bone. Endocrinology 139, 4319-4328.
14. Erben, R. G.; Mosekilde, L.; Thomsen, J. S.; Weber, K.; Stahr, K.; Leyshon, A.; Smith, S. Y.; Pjilipps, R., 2002: Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha, 25-dihydroxyvitamin D3. Journal of Bone and Mineral Research 17, 1498-1511.
15. Eriksen, E. F.; Hodgeson, S. F.; Eastell, R.; Ceel, S. L.; O' Fallon, W. M.; Riggs, B. L., 1990: Cancellous bone remodelling in type I (postmenopausal) osteoprosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. Journal of Bone and Mineral Research 5, 311-319.
16. Evans, C. H., 1990: Biochemistry of the Lanthanides. Plenum Press, New York and London.
17. FairweatherTait, S. J.; Dainty, J., 2002: Use of stable isotopes to assess the bioavailability of trace elements: a review. Food Additives and Contaminants 19, 939-947.
18. Fehmann, H. C.; Goke, R.; Goke, B., 1995: Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews 16, 390-410.
19. Fiddler, G.; Tanaka, T.; Webster, I., 2003: Low systemic absorption and excellent tolerability during administration of lanthanum carbonate (FosrenolTM) for 5days. In: 9th Asian Pacific Congress of Nephrology, February 19th-20th 2003, Pattaya, Thailand.
20. Finn, W. F., 2003: Efficacy and safety of long-term treatment with lanthanum carbonate - a novel phosphate-binding agent. In National Kidney Foundation Clincal Meeting 2003, Dallas, USA.
21. Fleckenstein, J.; Halle, I.; Hu, Z. Y.; Flachowsky, G.; Schnug, E., 2004: Analyse von Lanthaniden mittels ICP - MS in Futter- und Organproben im Broilermastversuch. In 22. Arbeitstagung Mengen und Spurenelemente, Jena, Germany, 2004.
22. Hamilton, J. G., 1949: The metabolism of the radioactive elements created by nuclear fisson. New England Journal of Medicine 240, 863-870.
23. Harada, S. I.; Rodan, G. A., 2003: Control of osteoblast function and regulation of bone mass. Nature 423, 349-355.
24. He, M. L.; Wang, Y. Z.; Xu, Z. R.; Chen, M. L.; Rambeck, W. A., 2003: Effect of dietary rare earth elements on growth performance and blood parameters of rats. Journal of Animal Physiololgy & Animal Nutrition 87, 229-235.
25. Heaney, R. P.; Nordin, B. E. C., 2002: Calcium effects on phosphorus absorption: implications for the prevention and co-therapy of osteoporosis. Journal of the American College of Nutrition 21, 239-244.
26. Hughes, F. J.; Turner, W.; Belibasakis, G.; Martuscelli, G., 2006: Effects of growth factors and cytokines on osteoblast differentiation. Periodontology 2000 41, 48-72.
27. Hutchison, A. J.; Speake, M.; Al-Baaj, F., 2004: Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose finding, open label study with lanthanum carbonate. Nephrology, Dialysis, Transplantation 19, 1902-1907.
28. Jaffe, M., 1886: Über den Niederschlag, welchen Pikrinsäure in normalem Harn erzeugt und über eine neue Reaction des Kreatinins. Hoppe-Seyler's Zeitschrift für physiologische Chemie 10, 391-400.
29. Ji, Y.; Cui, M.; Wang, Y.; Zhang, X., 1985: Toxicological study on safety evaluation of rare earth elements used in agriculture. In: G. Xu, J. Xiao (eds), New Frontiers in Rare Earth Science and Applications, Proceedings of the 1st International Conference on Rare Earth Development and Applications, 1985. Beijing, September 10-14, Science Press, Beijing, pp. 700-704.
30. Kalu, D. N., 1991: The ovariectomized rat model of postmenopausal bone loss. Bone and Mineral 15, 175-192.
31. Lau, K. H.; Baylink, D. J., 1999: Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcified Tissue International 65, 295-306.
32. Lepage, O. M.; Carstanjen, B.; Uebelhart, D., 2001: Non-invasive assessment of equine bone: an update. The Veterinary Journal 161, 10-23.
33. Lian, J. B.; Friedman, P. A., 1978: The vitamin K-dependent synthesis of gamma-carboxyglutamic acid by microsomes. Journal of Biological Chemistry 253, 6623-6626.
34. McClung, M.; Clemmesen, B.; Daifotis, A.; Gilchrist, N. L.; Eisman, J.; Weinstein, R. S.; Fuleihan El Hajj, G.; Reda, C.; Yates, A. J.; Ravn, P., 1998: Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Annals of Internal Medicine 128, 253-261.
35. National Institutes of Health, 2000: NIH Consens. Statement. 17, 1-45.
36. Nickel, R.; Schummer, A.; Seiferle, E., 2003: Lehrbuch der Anatomie der Haustiere, Band 1, Bewegungsapparat. Parey Verlag, Berlin, Germany.
37. Penning-van Beest, F. J. A.; Erkens, J. A.; Olson, M.; Herings, R. M. C., 2008: Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporosis International 19, 511-517.
38. Rambeck, W. A.; He, M. L., 2000: Rare earth elements - a new generation of growth promoters for pigs? Archives of Animal Nutrition, 53, 323-334.
39. Rambeck, W. A.; Wehr, U., 2005: Use of rare earth elements as feed additives in pig production. Pig News and Information 26, 1N-7N.
40. Reeve, J.; Meunier, P. J.; Parsons, J. A.; Bernat, M.; Bijovoet, O. L.; Courpron, P.; Edouard, C.; Klenerman, L.; Neer, R. M.; Renier, J. C.; Slovik, D.; Vismans, F. J.; Potts, J. T. J., 1980: Anabolic effects of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenter trial. British Medical Journal 280, 1340-1344.
41. von Rosenberg, S.; Wehr, U.; Bachmann, H., 2007: Effect of vitamin D-containing plant extracts on osteoporotic bone. Journal of Steroid Biochemistry and Molecular Biology 103, 596-600.
42. Rossouw, J. E.; Anderson, G. L.; Prentice, R. L.; LaCroix, A. Z.; Kooperberg, C.; Stefanick, M. L.; Jackson, R. D.; Beresford, S. A.; Howard, B. V.; Johnson, K. C.; Kotchen, J. M.; Ockene, J., 2002: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 288, 321-333.
43. Schmidt, C.; Priemel, M.; Kohler, T.; Weusten, A.; Müller, R.; Amling, M.; Eckstein, F., 2003: Precision and accuracy of peripheral quantitative computed tomography (pQCT) in the mouse skeleton compared with histology and microcomputed tomography (μCT). Journal of Bone and Mineral Research 18, 1486-1496.
44. Schmidt, B.; Adler, K.; Hellmann, K., 2008: The use of Renalzin, a new intestinal phosphate binder, in feline chronic renal failure. Proceedings of the Vetoalp 2008 Conference, March 2008, Chamonix, France: p. 69.
45. Shen, V.; Dempster, D. W.; Birchman, R.; Xu, R.; Lindsay, R., 1993: Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyreoid hormone and estradiol. Journal of Clinical Investigation 91, 2479-2487.
46. Shibata, T.; Sira-Ishi, A.; Sato, T.; Msaki, T.; Masuda, A.; Hishiya, A.; Ishikura, N.; Higashi, S.; Uchida, Y.; Saito, M. O.; Ito, M.; Ogata, E.; Watanabe, K.; Ikeda, K., 2002: Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. Journal of Bone and Mineral Research 17, 622-629.
47. Stracke, H.; Schatz, H.; Schmidt, A.; Schulz, A.; Federlin, K., 1990: Stimulation of bone growth by fluor or growth hormone. Calcified Tissue International 46, 11.
48. Trivedi, R.; Mithal, A.; Chattopadhyay, N., 2010: Anabolics in osteoporosis: the emerging therapeutic tool. Current Molecular Medicine 10, 14-28.
49. Tsukiyama, K.; Yamada, Y.; Yamada, C.; Harada, N.; Kawasaki, Y.; Ogura, M.; Bessho, K.; Li, M.; Amizuka, N.; Sato, M.; Udagawa, N.; Takahashi, N.; Tanaka, K.; Oiso, Y.; Seino, Y., 2006: Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Molecular Endocrinology 20, 1644-1651.
50. Waynforth, H. B., 1980: Experimental and Surgical Technique in the Rat. Academic Press, New York, NY, USA.
51. Wehr, U. A., 1998: Diagnosis, prevention and therapy of disorders in bone metabolism in humans: possibilities and limitations of biochemical bone markers. Med Vet Dissertation, Veterinary Faculty, Ludwig Maximilians University, Munich, Germany.
52. Xie, D.; Cheng, H.; Hamrick, M.; Zhong, Q.; Ding, K. H.; Correa, D.; Williams, S.; Mulloy, A.; Bollag, W.; Bollag, R. J.; Runner, R. R.; McPherson, J. C.; Insogna, K.; Isales, C. M., 2005: Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 37, 759-769.
53. Zhong, Q.; Itokawa, T.; Sridhar, S.; Ding, K. H.; Xie, D.; Kang, B.; Bollag, W. B.; Bollag, R. J.; Hamrick, M.; Insogna, K.; Isales, C. M., 2007: Effects of glucose-dependent insulinotropic peptide on osteoclast function. American Journal of Physiology-Endocrinology and Metabolism 292, 543-548.